Why Ivermectin, Azithromycin, Meplazumab and Vitamin D Helps to Control the Severity of SARS-CoV-2. The Role of ACE-2 and CD147 During Coronavirus Infection
Abstract
As the world faces pandemic of COVID-19, the search for effective treatments modalities against the disease and its complications has turned its gaze to drugs that are classically used in other infectious diseases. Some drugs are being examined for the recent evidence on its effects on viral replication and inflammation. The aim of the study was to review the mechanism of action of Ivermectin, Azithromycin, Hydroxycholoquine, and vitamin D therapy being used in the literature. This review found that the drugs might mitigate disease progression without significant adverse effects and can be used prophylactically, during the disease and after recover when in long hauler state. Further cohort studies are needed in order to extrapolate these findings in COVID-19. The discovery of CD147 will open the channel to discover some new more potent target therapeutic drugs.Keywords:
Coronavirus, COVID-19, Ivermectin. ACE2, CD147, Lucine, Histidine, SARS-CoV-2Published
2021/09/20
Issue
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments psimjournal@gmail.com